Free Trial
NASDAQ:EQ

Equillium Q4 2023 Earnings Report

Equillium logo
$0.50 -0.06 (-10.45%)
Closing price 04:00 PM Eastern
Extended Trading
$0.50 +0.00 (+0.77%)
As of 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Equillium EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.17
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

Equillium Revenue Results

Actual Revenue
$9.21 million
Expected Revenue
$8.85 million
Beat/Miss
Beat by +$360.00 thousand
YoY Revenue Growth
N/A

Equillium Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, March 25, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Equillium's Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Friday, August 15, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Equillium Earnings Headlines

The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”
See More Equillium Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Equillium? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Equillium and other key companies, straight to your email.

About Equillium

Equillium (NASDAQ:EQ), a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

View Equillium Profile

More Earnings Resources from MarketBeat